Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2416 to 2430 of 8213 results

  1. Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]

    Awaiting development Reference number: GID-TA11517 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]

    In development Reference number: GID-TA11235 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]

    Awaiting development Reference number: GID-TA11281 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]

    Awaiting development Reference number: GID-TA11470 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]

    In development Reference number: GID-TA10664 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]

    Awaiting development Reference number: GID-TA10971 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. MT547 QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  8. Suspected cancer update

    In development Reference number: GID-QS10176 Expected publication date: TBC

    Quality standard
    In development

  9. Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]

    Awaiting development Reference number: GID-TA11137 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Zoll ThermoGuard XP for Intravascular Temperature Management

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  11. DOASENSE DOAC dipstick product for the detection of direct oral anti-coagulants

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  12. CytoSorb for reducing risk of bleeding during cardiac surgery

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  13. Moor LDLS-BI for assessing burn depth and healing potential in children and adults

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  14. The Stak for knee stretching following knee replacement or injury or to treat osteoarthritis

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  15. URO17 for testing suspected bladder cancer

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation